Professor Erika Lietzan is a “Membre Associé” at the Centre de Recherche sur le Droit Des Marchés et des Investissements Internationaux (CREDIMI), which is part of the Faculty of Laws, Economics, and Politics of Dijon, within the University of Bourgogne in Dijon, France. The CREDIMI focuses on the study of the market, its functioning, and its players, including specific sectoral…
Category: Center for Intellectual Property and Entrepreneurship ⋅ Page 1
Professor Lietzan Appointed to Food and Drug Law Leadership Positions
Professor Erika Lietzan has been appointed co-chair of the annual conference of the Food and Drug Law Institute (FDLI). FDLI is a non-profit organization focused on food and drug law, supported by members from FDA, the food and drug bar, lawyers and regulatory specialists within the regulated industries, and academics specializing in FDA law. She has been a member of…
Boston College Law Review Publishes Article by Professor Lambert
Professor Thom Lambert’s article, Mere Common Ownership and the Antitrust Laws, appears in the latest edition of the Boston College Law Review. Professor Lambert criticizes claims by prominent antitrust scholars and the leading antitrust treatise that institutional investors’ ownership of minority stakes in competing firms may violate the U.S. antitrust laws. The article follows up on an earlier common ownership article…
Professor Lambert interviewed by the Global Antitrust Institute
Professor Thom Lambert was recently interviewed about his paper, Rent-Seeking and Public Choice in Digital Markets. The paper will soon be published as a chapter in the Global Antitrust Institute’s forthcoming Report on the Digital Economy. The interview is on YouTube. Professor Lambert explains public choice theory and the concept of rent-seeking and then describes a number of recent instances of…
Professor Barondes publishes in the Texas Review of Law & Politics
Professor Royce Barondes recently had an article accepted for publication in the Texas Review of Law & Politics. In the article, he examines contemporary jurisprudence holding a person who has a prior felony conviction is not “virtuous” and, thus, has forfeited his or her rights under the Second Amendment. The article surveys the circumstances in which contemporary courts have relied…
Professor Lietzan named a “Best Lawyer in America” for 2020
Professor Erika Lietzan has again been named a “Best Lawyer in America” in both FDA Law and Biotechnology & Life Sciences. This marks the seventh year in a row for FDA Law and the thirteenth year in a row for Biotechnology Law. The Best Lawyers honor is meant to identify the top 5 percent of practicing attorneys in the United…
Professor Lietzan Among New Public Members of the Administrative Conference
Professor Erika Lietzan has been appointed as one of eight new public members of the Administrative Conference of the United States (ACUS). ACUS is an independent federal agency dedicated to improving the administrative process through consensus-driven applied research and providing nonpartisan expert advice and recommendations for federal agency procedures. Its public members are academics, practicing lawyers, and other experts drawn…
Professor Lietzan publishes in Yale Journal of Health Policy, Law, and Ethics
Professor Erika Lietzan has published a new article, Early Access to Unapproved Medicines in the United States and France, 19 Yale J. Health Pol’y L. & Ethics (2020). She, along with co-author Isabelle Moine-Dupuis, wrote about the new U.S. law on early access to experimental medicine. Lietzan and Moine-Dupuis explore the historical, legal, and cultural differences in the early access systems…
Professor Crouch publishes post #7,000 on Patently-O
This month Professor Dennis Crouch published his 7,000th post on Patently-O. The academic blog is a daily read for most U.S. patent law professionals and has been cited in over 1,000 law review…
Professor Lietzan speaks at The Federalist Society’s COVID-19 & the Law Conference
Professor Erika Lietzan spoke at The Federalist Society’s COVID-19 & the Law Conference, contributing to the panel Regulation or “Don’t Let a Good Crisis Go to Waste.” She focused on decisions by regulators to de-regulate during the crisis — decisions to exercise enforcement discretion, to waive paperwork requirements, and to remove otherwise applicable restrictions — including decisions made by FDA…